About the Authors

Parag R. Gajendragadkar

Affiliation Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom

Annette Hubsch

Affiliation Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom

Kaisa M. Mäki-Petäjä

Affiliation Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom

Martin Serg

Affiliations Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom, Department of Cardiology, University of Tartu, Tartu, Estonia

Ian B. Wilkinson

Affiliations Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom, Cambridge Clinical Trials Unit, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom

Joseph Cheriyan

jc403@cam.ac.uk

Affiliations Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom, Cambridge Clinical Trials Unit, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom

Competing Interests

The authors declare the following: Cambridge Theranostics donated drugs and placebo to the study. Ateronon, a food supplement, is a registered trademark of CamNutra. The authors acknowledge unrestricted educational donations made by Cambridge Theranostics and CamNutra to Addenbrooke’s Charitable Trust. The donations were unrelated to the trial, which was not funded by either company. The commercial companies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: JC IBW. Performed the experiments: PRG AH KMM MS IBW JC. Analyzed the data: PRG AH MS KMM JC. Contributed reagents/materials/analysis tools: PRG AH KMM MS IBW JC. Wrote the paper: PRG AH KMM MS IBW JC.